Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens

International Journal of Antimicrobial Agents

Volumn 29, Issue 1, 2007, Pages 39-43

  Stein, Gary E ^a   Schooley, Sharon ^a   Tyrrell, Kerin L ^b   Citron, Diane M ^b   Goldstein, Ellie J C ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b R M ALDEN RESEARCH LABORATORY   (United States)

Author keywords

Amoxicillin clavulanate; Azithromycin; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAMASE; TELITHROMYCIN;

ADULT; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ARTICLE; ASPIRATION PNEUMONIA; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CHRONIC SINUSITIS; DRUG ACTIVITY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PEPTOSTREPTOCOCCUS; PEPTOSTREPTOCOCCUS MAGNA; PEPTOSTREPTOCOCCUS MICROS; PHARMACODYNAMICS; PREVOTELLA BIVIA; PREVOTELLA MELANINOGENICA; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, ORAL; ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIA; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; KETOLIDES; MALE; MIDDLE AGED; PEPTOSTREPTOCOCCUS; PREVOTELLA; PREVOTELLA MELANINOGENICA; SERUM BACTERICIDAL TEST; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 33845679788     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.08.041     Document Type: Article

References (22)

1. Goldstein E.J.C. Selected nonsurgical anaerobic infections: therapeutic choices and the effective armamentarium. Clin Infect Dis 18 Suppl. 4 (1994) 273-279
2. Nord C.E. The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis 20 (1995) 1512-1524
3. Brook I., and Finegold S.M. Bacteriology of chronic otitis media. JAMA 241 (1979) 487-488
4. Levison M.E. Anaerobic pleuropulmonary infection. Infect Dis Clin Prac 11 (2003) 131-136
5. Goldstein E.J.C., Conrads G., Citron D.M., Merriam C.V., Warren Y., and Tyrrell K. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Diagn Microbiol Infect Dis 42 (2002) 113-118
6. Stein G.E., Schooley S., Tyrrell K.L., Citron D.M., and Goldstein E.J.C. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 47 (2003) 1308-1312
7. Lonks J.R., and Goldman D.A. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 40 (2005) 1657-1664
8. Wexler H.M., Molitoris E., Molitoris D., and Finegold S.M. In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria. J Antimicrob Chemother 47 (2001) 467-469
9. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y., Tyrrell K.L., and Fernandez H. In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis. Antimicrob Agents Chemother 47 (2003) 1963-1967
10. Zhanel G.G., Johanson C., Hisanaga T., et al. Pharmacodynamic activity of telithromycin against macrolide-suseptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother 54 (2004) 1072-1077
11. Kuehnel T.S., Schurr C., Lotter K., and Kees F. Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis. J Antimicrob Chemother 55 (2005) 591-594
12. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - 6th ed. Approved standard, CLSI document M7-A6, vol. 23. Wayne, PA: CLSI; January 2003.
13. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Methods for antimicrobial susceptibility testing of anaerobic bacteria - 6th ed. Approved standard, CLSI document M11-A6, vol. 24. Wayne, PA: CLSI; January 2004.
14. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards Institute (NCCLS)]. Methodology for the serum bactericidal test; approved guideline. CLSI document M21-A, vol. 19. Wayne, PA: CLSI; September 1999.
15. Fuchs P.C., Barry A.L., and Brown S.D. In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime. J Antimicrob Chemother 49 (2002) 399-401
16. Fogarty C.M., Kohno S., Buchanan P., Aubier M., and Baz M. Community-aquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother 51 (2003) 947-955
17. Odenholt I., Lowdin E., and Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 45 (2001) 23-29
18. Bonnefay A., and Le Priol P. Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics. J Antimicrob Chemother 47 (2001) 471-473
19. Alferova I.V., Vostrov S.W., Portnoy Y.A., Lubenko I.Y., Zinner S.H., and Firsov A.A. Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. Int J Antimicrob Agents 26 (2005) 197-204
20. Dandekar P.K., Williams P., Tessier P.R., Farrell D.J., Nightingale C.H., and Nicolau D.P. Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model. Int J Antimicrob Agents 25 (2005) 530-534
21. Kays M.B., White R.L., and Friedrich L.V. Effect of serum from different populations on the serum bactericidal test. J Antimicrob Chemother 48 (2001) 417-420
22. Khair O.A., Andrews J.M., Honeybourne D., Jevons G., Vacheron F., and Wise R. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 47 (2001) 837-840